Eduardo Luna, MD
Endocrinology, Diabetes & Metabolism · Edinburg, TXNPI 1073959326
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $991,999 of the $1,285,306 with a category attached, or 77.2%. 38 manufacturers reported payments, led by Lilly USA, LLC at 37.8% of the total. 2025 is the largest year on record at $299,263, more than ten times the $24,743 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,526 payments — averaging $508.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$485K
- Corcept Therapeutics$347K
- AstraZeneca$121K
- Abbott$115K
- Dexcom, Inc.$78K
- Insulet Corporation$45K
- plus $95K from 32 others
Across 120 payments — averaging $53,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6M
- AbbVie$359K
- Novartis$32K
- Harmony Biosciences LLC$24K
- Eli Lilly Export S.A. Puerto Rico Branch$14K
- Amgen$306
What the payments were for
- Consulting fees$30,6802%
- Speaking & faculty fees$991,99977%
- Travel & lodging$220,38117%
- Food & beverage$41,2483%
- Education$9980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$341,901
- MOUNJARO$201,717
- TRULICITY$143,288
- DEXCOM G7 GSS (161)$50,585
- FreeStyle Libre Pro$45,912
- Omnipod$43,203
- ISTURISA$34,649
- Strensiq$29,631
- FREESTYLE LIBRE 3$27,165
- DEXCOM G6 TRANSMITTER$26,058
- FreeStyle Libre$25,568
- REZDIFFRA$23,491
- FreeStyle Libre 2$12,689
- DEXCOM STELO GLUCOSE BIOSENSOR$11,835
- AFREZZA$10,846
- RECORLEV$7,965
- CeQur Simplicity$6,183
- Lynkuet$1,715
- Mitra Clip system$1,250
- Eversense$1,040
How this compares
$1,285,306 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 120 | $4,706,052 |
| StrensiqAsfotase Alfa | 23 | $1,235,434 |
| MounjaroTirzepatide | 797 | $1,085,838 |
| OzempicSemaglutide | 230 | $327,897 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 195 | $230,808 |
| JardianceEmpagliflozin | 133 | $161,727 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 86 | $118,780 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 43 | $113,276 |
| TrulicityDulaglutide | 66 | $92,931 |
| Tresiba Flextouch U-200Insulin Degludec | 109 | $75,778 |
| AfrezzaInsulin Regular, Human | 43 | $68,906 |
| TymlosAbaloparatide | 22 | $65,910 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $50,921 |
| FarxigaDapagliflozin Propanediol | 42 | $49,631 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 37 | $40,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $346,752 | $4,706,052120 claims |
| AstraZenecaStrensiq, Farxiga | $120,531 | $1,285,06565 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $485,298 | $1,190,275908 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr, Glyxambi, Tradjenta | $383 | $484,259413 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,629 | $374,097279 claims |
| AmgenEvenity (2 Syringes), Prolia | $659 | $146,81363 claims |
| Mannkind CorporationAfrezza | $11,542 | $68,90643 claims |
| Radius Health, Inc.Tymlos | $1,137 | $65,91022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Edinburg
- Surya MulukutlaEdinburg$195K
- Alejandro Gonzalez CamposEdinburg$185K
- Jose Llinas CepedaEdinburg$136K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.